Default company panoramic image

QE Chemicals, Inc.

Azaborine synthetic building blocks provide structural diversity and novel biochemical reactivity, expanding chemists' ability to innovate.

  • Stage Product In Development
  • Industry Other
  • Location Eugene, OR, USA
  • Currency USD
  • Founded July 2011
  • Employees 2
  • Website

Company Summary

QE makes and sells novel synthetic building blocks as research tools based on azaborine chemistry. Our customers are industrial and academic chemists worldwide. The products are used to create novel molecules and libraries that enhance structure-activity relationships, and yield new biological responses, e.g., an enzyme substrate was converted to an inhibitor by installing azaborine in place of phenyl. Thus, innovation is supported and enhanced.


  • Default avatar
    Donald A. Upson
    Chief Executive Officer

    Chemist with PhD and 27 years industrial experience, 21 in management including 8 as director of medicinal chemistry at Sterling Winthrop and 4 as VP of a biotech research tools company Molecular Probes. Ten years in academia, including 8 as director of MBA venture launch pathway at U of Oregon business school. Co-founder of 3 startups, including QE Chemicals.

  • Default avatar
    Shih-Yuan Liu
    Chief Scientific Officer

    PhD organic chemist and Associate Professor of Chemistry at the University of Oregon. Co-founder of QE Chemicals and world's expert in azaborine chemistry.

  • Default avatar
    Ashley N. Lamm
    Senior Chemist

    PhD organic chemist, trained in the Liu group at U of Oregon and an expert in azaborine chemistry. Ashley is creating an azaborine analog of acetaminophen, which is an object of our STTR project to prove that the analog cannot form the toxic metabolite that forms with commercial acetaminophen.

  • Default avatar
    Adam Marwitz
    Senior Chemist

    Ph.D. organic chemist, trained in the Liu group at U of Oregon, and currently serving as a post-doc in that group supporting the U of Oregon objectives of our STTR grant and responsible for cost engineering and scale-up supported by our ONAMI grant .

  • Default avatar
    August J. Sick

    Co-founder and managing director of Cascade Pro-Drug; Entrepreneur in Residence for the Oregon Nanotechnologies and Microproducts Institute (ONAMI); 25 years of executive experience, including President of Molecular Probes, a catalog specialty chemicals business similar to QE.

  • Default avatar
    Daniel A. Vishny

    MBA with 20 years as a CPA and CFO for a number of firms, including Spirit Leatherworks, Dune Sciences. CEO of Red Ape Cinnamon.

  • Default avatar
    Allan G. Cochrane

    Former President of Microprobe, which he took public on NASDAQ. President and COO of Saigene for 10 years. Co-founder of Cascade Prodrug. Co-founder of In the Loop, LLC. Mr Cochrane is the "deal guy" in QE's corner, having completed several dozen over his entrepreneurial career.


  • Default avatar
    Katherine Moyer
    Default avatar
    Daniel Vishny and Chris Valentine